24/7 Market News Snapshot 10 July, 2025 – Calidi Biotherapeutics, Inc. (NYSE:CLDI)

July 10, 2025

DENVER, Colo., 10 July, 2025 (www.247marketnews.com) – (NYSE:CLDI) are discussed in this article.
Calidi Biotherapeutics, Inc. (CLDI) has recently experienced remarkable growth, with its stock price climbing from $0.70 at the previous close to an impressive $0.87, reflecting a 24.29% increase in a single day. This surge has attracted significant investor interest, as evidenced by a trading volume of 25.19 million shares. Such momentum underscores the company’s potential within the biotechnology sector, particularly as it focuses on developing innovative biotherapeutic solutions.

In tandem with its stock market performance, Calidi Biotherapeutics has garnered attention through a feature in an editorial published by NetworkNewsWire (NNW). The piece, titled “Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers,” highlights the pressing need for advanced oncological treatments as cancer diagnoses are projected to escalate to 35 million annually by 2050, according to the American Cancer Society. In response to this challenge, Calidi is at the forefront of creating a revolutionary platform for delivering genetic medicines directly to both primary and metastatic tumors.

Utilizing engineered viruses to transport therapeutic agents with high precision, Calidi Biotherapeutics aims to enhance treatment efficacy while prioritizing patient safety. Although oncology remains central to its mission, the company is also investigating applications for its advanced technologies in other medical areas, particularly autoimmune disorders. By leveraging its unique stem cell-based platforms capable of administering potent oncolytic viruses, Calidi is positioning itself as a key player among biotech innovators striving to advance cancer therapies.

Through its commitment to addressing the significant challenges faced by cancer patients, Calidi Biotherapeutics is poised to make substantial contributions to the evolution of treatment paradigms in oncology, ultimately seeking to improve patient outcomes on a global scale.

Related news for (CLDI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.